PWAM
KROS icon

Private Wealth Asset Management’s Keros Therapeutics KROS Stock Holding History

Private Wealth Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.52K Hold
500
– – ﹤0.01% 772
2025
Q4 		$10.2K Buy
+500
New +$8.77K ﹤0.01% 668

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Private Wealth Asset Management's KROS Position: Q1 2026 in Review

Private Wealth Asset Management held its Keros Therapeutics (KROS) position steady in Q1 2026 at 500 shares worth $5.52K. The position accounts for ﹤0.01% of the portfolio, ranked #772.

Private Wealth Asset Management first reported a position in KROS in Q4 2025 and has held it in 2 quarters since. The position peaked at $10.2K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Private Wealth Asset Management held 500 shares of Keros Therapeutics worth $5.52K as of Q1 2026.
  • Private Wealth Asset Management left its Keros Therapeutics share count unchanged in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Private Wealth Asset Management's portfolio in Q1 2026, its #772 holding.
  • Private Wealth Asset Management first reported a position in Keros Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Private Wealth Asset Management's Keros Therapeutics position peaked at $10.2K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Private Wealth Asset Management's 13F filing for Q1 2026, filed 6 May 2026.